You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company will use the funds to develop and refine proprietary algorithms for identifying more complex variants including translocations and inversions.
The firm will use the funds to advance its high-throughput single-cell analysis platform to analyze heterogeneity in cell populations for research and drug discovery.
Fueled by an NIH SBIR grant, analytics firm Cytobank is building out its machine-learning algorithms and adding pipelines to support big-picture research.
The firm plans to make the molecular testing system accessible to low-income countries, in part by reducing costs using reel-to-reel manufacturing.
The automated, whole-genome directional genomic hybridization system can measure de novo random, low-frequency, and complex structural variations.
As part of an NIH SBIR grant, Genomenon is automating the curation of medical literature in its Mastermind variant interpretation software.
The company said it will use the funding to accelerate the development of an affordable sequencing test for metagenomic samples.
The firm plans to integrate its technology with a compatible microfluidic sample prep method developed by researchers at Columbia University.
SolveBio is continuing development of a cloud-based genetic variation analysis and visualization system called Variant Explorer.
The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.